Capsules vs Powders vs Sublingual: Which Form Matters

The same compound in different forms can produce meaningfully different effects. Sublingual administration bypasses first-pass hepatic metabolism; capsules deliver a slower release into the small intestine; powders allow custom dosing but introduce variability. The right form depends on the compound's pharmacokinetics and the user's intended use.

Capsules

The dominant form because of convenience. Pre-measured dose, no taste, portable, predictable absorption.

Best for: compounds taken regularly at fixed doses (Bacopa, Ashwagandha, omega-3, vitamins, magnesium). Compounds whose taste is problematic. Compounds where slow release improves tolerability.

Limitations: fixed doses lack the flexibility of powder. The capsule shell adds a small dissolution lag. Some delayed-release capsules can produce inconsistent timing.

For most compounds, capsules are the default form and produce the published clinical effects.

Powders

Allow custom dosing in 10 mg increments (with appropriate milligram scale). Lower cost per dose for the same content. Bulk powders can save 30-50% over capsule pricing.

Best for: amino acids in larger doses (tyrosine, theanine, creatine, glycine). Compounds where the user wants precise titration. Compounds taken pre-workout in a drink.

Limitations: require a milligram scale ($30-50) for accurate dosing. Many compounds taste unpleasant. Powders absorb moisture from air; storage requires care. Some powders (vitamin D3) require precise dosing at very low weights that consumer scales can't measure.

Powder-form compounds where the difference matters most: theanine, tyrosine, creatine (the bulk powder economics are substantial), glycine (3 g doses are impractical in capsules), beta-alanine (split dosing for paresthesia management).

Sublingual

Held under the tongue for 30-60 seconds before swallowing. The sublingual mucosa absorbs lipophilic compounds rapidly, bypassing hepatic first-pass metabolism.

Best for: compounds with poor oral bioavailability (B12, methylcobalamin sublingual has excellent bioavailability compared to capsules), compounds where fast onset is desired (melatonin for sleep onset, nicotine for cognitive use), compounds where first-pass metabolism destroys the active form.

Compounds where sublingual is clearly better than oral: vitamin B12 (especially in users with absorption issues), low-dose melatonin (faster onset), some forms of testosterone replacement (clinical use), vitamin D3 for users with absorption issues.

Compounds where sublingual is marketed but not clearly better: most nootropics. The marketing claim of "sublingual for faster absorption" is often true for water-soluble compounds (which absorb fine orally) but doesn't produce meaningfully different effects.

NMN sublingual vs oral: marketing claims of better absorption are not well-supported by pharmacokinetic data. The differences are small.

Glutathione sublingual: marketing claim of bypassing the BBB problem isn't supported by clinical data.

Liposomal and nanoparticle forms

Engineered forms that encapsulate the active compound in lipid spheres for improved absorption.

Useful for: curcumin (Meriva phytosome, NovaSOL micelle), CoQ10 (some products), vitamin C (the high-dose oral protocols use liposomal).

Marketing claim vs reality varies. Liposomal vitamin C clearly produces higher plasma levels than standard. Liposomal glutathione's central effects are less clear.

The price premium can be 3-5x standard form. Worth it for compounds with severe bioavailability problems (curcumin); less worth it for compounds that absorb fine orally.

Sprays, lozenges, gummies

Sprays (typically B12, melatonin) are reasonable for users who can't swallow capsules. The bioavailability is similar to sublingual.

Lozenges deliver compounds slowly through the oral mucosa. Nicotine lozenges are the most common nootropic application. Some vitamin lozenges.

Gummies typically use higher sugar content and lower active doses than capsules. Convenience tax, useful for users who won't take capsules but typically deliver less active per dose.

Injectable and intranasal

For research chemicals and some peptides (semax, selank, BPC-157, dihexa). Intranasal delivery bypasses BBB and first-pass metabolism for some peptides.

Generally outside the scope of supplement use; specialty applications under medical or research oversight.

Per compound

Caffeine: any form works. Capsules are convenient; coffee delivers caffeine plus other actives; pre-workout drinks deliver alongside other compounds.

L-theanine: capsules or powder both fine. Sublingual marketing isn't well-supported.

Magnesium glycinate: capsules work. Powder if you want larger custom doses.

Magnesium L-threonate: capsules. The compound is moisture-sensitive in powder form.

Melatonin: low-dose sublingual is genuinely faster. Standard capsule is fine for nightly use where timing is consistent.

Bacopa: capsule of standardised extract is the form used in clinical trials.

Ashwagandha (KSM-66 etc): capsules.

Creatine: bulk powder is far more economical than capsules. The compound is stable and tasteless.

NR/NMN: capsules. Sublingual claims aren't well-supported.

Curcumin: bioavailable forms (Meriva, Theracurmin) come in capsules.

Vitamin B12: sublingual methylcobalamin clearly outperforms capsule cyanocobalamin for many users.

Vitamin D3: any form works at standard doses. Liquid drops for very low dose precision.

The practical default

For 90% of users and 90% of compounds, capsules are the right form. The convenience advantage outweighs minor pharmacokinetic differences for compounds with normal oral bioavailability.

Powder makes sense for high-dose amino acids and creatine where the cost difference is substantial.

Sublingual makes sense for melatonin specifically (faster onset) and B12 specifically (better absorption).

Liposomal makes sense for compounds with severe bioavailability problems (curcumin, vitamin C at very high doses).

Skip novelty forms unless there's clinical evidence supporting the choice. Most form innovations are marketing decoration that don't meaningfully change clinical outcomes.